Lamotrigine is an antiepileptic drug that has been widely used for epilepsy, as a mood stabilizer (for type 1 bipolar disorder) and in the management of neuropathic pain, it both monotherapy complementary therapy. Considered relatively new, approved by Food Drug Administration 1994, its benefits include greater margin safety compared to other anticonvulsants. However, although lower percentage,...

BACKGROUND The choice of antiepileptic drug for an individual should be based upon the highest quality evidence regarding potential benefits and harms of the available treatments. Systematic reviews and meta-analysis of randomised controlled trials should be a major source of evidence supporting this decision making process. We summarise all available individual patient data evidence from rando...

OBJECTIVE Antiepileptic drugs (AEDs) may have adverse effects on bone mineral density (BMD) and metabolism. We previously reported biochemical evidence of increased bone turnover in premenopausal women with epilepsy on phenytoin monotherapy compared with those on carbamazepine, lamotrigine, and valproate. We therefore hypothesized that rates of bone loss would be higher in young women treated w...

PURPOSE To evaluate the effects on vision in patients receiving lamotrigine (LTG) monotherapy. METHODS Twenty-four consecutive patients taking LTG for partial seizures were referred for a routine ophthalmologic examination including visual acuity testing, tonometry, slit lamp, and fundus examination. Automated kinetic perimetry, electrooculogram (EOG), and electroretinogram were performed aft...

Lamotrigine is licensed for first-line monotherapy use in the United Kingdom but many physicians have been reluctant to use it because of its perceived increased cost over conventional first-line antiepileptic medication. Clinical trials, however, have suggested that it has equivalent efficacy to conventional drugs in this role, with a significantly reduced side effect profile. It has been the ...

OBJECTIVES To determine the clinical effectiveness and cost-effectiveness of pharmacological and/or psychosocial interventions for the prevention of relapse in people with bipolar disorder. DATA SOURCES Major electronic databases were searched up to September 2005. REVIEW METHODS Systematic reviews were undertaken on the clinical and economic effectiveness of treatments. An analysis was per...

OBJECTIVES To describe prescribing patterns for older veterans with epilepsy, determine whether disparity exists between these patterns and clinical recommendations, and describe those at greatest risk of receiving potentially inappropriate antiepileptic drugs (AEDs). DESIGN Retrospective administrative database analysis. SETTING All outpatient facilities within the Department of Veterans A...

PURPOSE To evaluate the efficacy and tolerability of lamotrigine monotherapy in children with paroxysmal kinesigenic dyskinesia. METHOD A sample of eighteen children aged between 2 years old and 13 years old who fulfilled the diagnostic criteria from January 2008 to December 2014 was enrolled, they received video electroencephalography, brain image scans and proline-rich transmembrane protein...

PURPOSE We previously demonstrated that converting patients from the enzyme-inducers phenytoin or carbamazepine to the non-inducers levetiracetam or lamotrigine reduces serum lipids and C-reactive protein (CRP). We sought to determine if the same changes would occur when patients were switched to topiramate, which has shown some evidence of enzyme induction at high doses. We also examined the e...

Main results 0.40% of children were exposed to antiepileptic drugs during pregnancy; 0.08% were exposed to valproate. 0.83% of children were diagnosed with autism spectrum disorder during follow-up, including 0.32% with childhood autism. Use of valproate during pregnancy was associated with increased risk for autism spectrum disorder and childhood autism in offspring (Table). Other antiepilepti...